Glad to hear things are improving on the regulations front. Sales is going to be hard for a while, but I think that there are some markets where this is less of

Glad to hear things are improving on the regulations front. Sales is going to be hard for a while, but I think that there are some markets where this is less of an issue, as it's more cash-based anyway. It makes me sad, though, that a lot of the population-based preventative stuff for which AI would be a great fit is unlikely to be a financially appealing investment.